Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
IMC-2034 by ImmuneCyte for Premature Ovarian Failure: Likelihood of Approval
IMC-2034 is under clinical development by ImmuneCyte and currently in Phase I for Premature Ovarian Failure. According to GlobalData, Phase...